Patent covers brilaroxazine use for treating Pulmonary Fibrosis-Similar patents have also been granted in key markets around the world ...

Growth is driven by rising COPD cases due to smoking and pollution, and enhanced therapeutic options like bronchodilators and biologics. Significant investments are improving diagnosis and treatment.

BOSTON, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Avalyn Pharma Inc., a clinical-stage biopharmaceutical company focused on the development of inhaled therapies for the treatment of life-threatening pulmonary ...

Opinion - Liberia's journey toward sustainable development and economic independence has been closely linked to its performance on the Millennium Challenge Corporation (MCC) scorecard. Between 2016 ...

Q3 2025 Earnings Call Transcript November 14, 2025 Operator: Good morning, ladies and gentlemen, and thank you for standing ...

The Union government has directed states and Union territories to establish a robust public health response, including ...

Cereno Scientific (Nasdaq First North: CRNO B), an innovative biotech pioneering treatments to enhance and extend life for people with rare cardiovascular and pulmonary diseases, today announced the ...

MannKind has made the decision to discontinue the ICoN-1 Phase 3 clinical trial evaluating nebulized clofazimine inhalation ...

Received FDA IND clearance to evaluate CDI-988 as both norovirus preventive and treatmentExpects to initiate CDI-988 Phase 1b ...

October 2025 saw a wave of M&As and biotech deals in various therapeutic fields, particularly for therapies addressing ...

Although rare kidney diseases remain a significantly overlooked contributor to the global burden of CKD, things have begun to ...

A pioneering patient-reported outcome tool, developed by healthcare company Observia with the support of Kingston University ...